Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.26.1
Segment Information
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information

7. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

 

The CODM, who is the Chief Executive Officer (“CEO”), President, and Chairman of the Board, manages and allocates resources to the operations of the Company on an entity-wide basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on an entity-wide basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.

 

Given the Company’s September 2025 strategic pivot to prioritize the development and distribution of Tome skincare products, the segment information disclosure has been recast for all periods presented to reflect this change. The following table summarizes the segment’s financial information including the Company’s significant segment expenses:

 

    2026     2025  
   

Three Months Ended

March 31,

 
    2026     2025  
Research and development   $         $      
Clinical     -       726,321  
Chemistry, manufacturing and controls and nonclinical     32,502       125,290  
Personnel related     351,222       429,530  
Total research and development   $ 383,724     $ 1,281,141  
Selling, general and administrative                
Compliance     1,011,796       719,644  
Marketing     206,333       -  
Personnel related     324,529       339,018  
Total selling, general and administrative     1,542,658       1,058,662  
Interest income     78,676       36,216  
Net loss   $ (1,847,706 )   $ (2,303,587 )